**Exeporfinium Chloride (XF-73) Nasal Gel Significantly Reduces *Staphylococcus aureus* Nasal Carriage in Cardiac Surgery Patients Throughout Surgery and the Early Recovery Period: Results from Randomized Placebo-Controlled Phase 2 Study**

**SUPPLEMENTARY MATERIAL**

Julie E Mangino MD, FSHEA, FIDSA,1 Michael S Firstenberg MD, FACC, FAIM,2 William Rhys-Williams PhD3, James P. Lees BSc5, Aaron Dane MSc4, William G. Love PhD3, Jesus Gonzalez Moreno MD5, Yuri Martina MD PhD5, Debra Barker MD3

1 Division of Infection Diseases, Department of Internal Medicine, The Ohio State University – Columbus, OH (United States)

2 Department of Surgery, Maui Memorial Medical Center – Maui, HI (United States)

3 Destiny Pharma plc – Brighton (United Kingdom)

4 Danestat Consulting Ltd. – Macclesfield (United Kingdom)

5 Formerly at Destiny Pharma plc – Brighton (United Kingdom)

**Figure A: Study Flow Chart**

**A diagram of a company

Description automatically generated**

CFU = colony forming units; n = number of patients.

Table 1: Demographics and Baseline Characteristics (micro-ITT Set)

|  |  |  |  |
| --- | --- | --- | --- |
| Demographic Characteristics | **0.2% w/w XF‑73**  **(N=43)** | Placebo  (N=40) | Overall (N=83) |
| **Age, years** | | | |
| Mean (SD) | 59.7 (10.94) | 61.5 (7.22) | 60.6 (9.33) |
| Median (range) | 61.0 (18, 75) | 62.5 (43, 73) | 62.0 (18, 75) |
| **Sex, n (%)** | | | |
| Male | 31 (72.1) | 32 (80.0) | 63 (75.9) |
| Female | 12 (27.9) | 8 (20.0) | 20 (24.1) |
| **Obesity** | | | |
| BMI ≥30kg/m2, n (%) | 21 (48.8) | 20 (50.0) | 41 (49.4) |
| Mean BMI (SD) | 30.27 (4.65) | 30.75 (4.58) | 30.50 (4.59) |
| Median BMI (range) | 30.03 (20.76, 44.57) | 30.14 (20.80, 40.39) | 30.14 (20.76, 44.57) |
| **Diabetic Status, n (%)** | | | |
| Diabetes Mellitus | 16 (37.2) | 16 (40) | 32 (38.6) |
| Receiving oral agents and/or insulin | 14 (32.6) | 13 (32.5) | 27 (32.5) |
| **Country of enrollment, n (%)** | | | |
| USA | 2 (4.7) | 1 (2.5) | 3 (3.6) |
| Georgia | 37 (86.0) | 37 (92.5) | 74 (89.2) |
| Serbia | 4 (9.3) | 2 (5.0) | 6 (7.2) |
| **Mean duration of post-operative antibiotic administration** | 7.57 days  [SD =5.53] | 7.77 days  [SD = 7.05] |  |
| Planned surgical and medical procedures, n (%) [FI] | | | |
| Coronary artery bypass grafting (CABG) | 26 (60.5) [1] | 21 (52.5) [0] | 47 (56.6) [1] |
| CABG + valve | 3 (7.0) [3] | 3 (7.5) [3] | 6 (7.2) [6] |
| Mitral valve replacement & repair | 7 (16.3) [5] | 7 (17.5) [5] | 14 (16.9) [10] |
| Aortic Valve replacement (AVR) | 6 (14.0) [6] | 8 (20.0) [8] | 14 (16.9) [14] |
| Aortic aneurysm repair | 1 (2.3) [1] | 1 (2.5) [1] | 2 (2.4) [2] |
| Undergone surgery, n (%) [FI] | **43 (100.0) [16]** | 40 (100.0) [17] | 83 (100.0) [33] |

BMI = body mass index; ITT = intent-to-treat; SD = standard deviation; FI = foreign implant (e.g., aortic graft, biologic/mechanical valve, or mitral annuloplasty ring).